By James A. White After its stock fell off a cliff yesterday only to soar back later, Dendreon is looking no worse for wear today. In fact, it was looking all the better to some on Wall Street as a potential takeover target.
Analysts are focusing on study data for its new prostate cancer treatment Provenge rather than the latest stock gyrations. Reuters notes the seven analysts following the company had two “sell” ratings and five “hold” ratings on the stock a little more than two weeks ago; now now five have “buy” or “outperform” and two have “holds.”